Details of the Drug

General Information of Drug (ID: DMPDW6T)

Drug Name
Epirubicin
Synonyms
Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01DB03: Epirubicin
L01DB: Anthracyclines and related substances
L01D: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 543.5
Logarithm of the Partition Coefficient (xlogp) 1.3
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
Absorption
The absorption of drug is 100% []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 20 mL/min/kg [3]
Elimination
9.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 minutes (alpha), 2.5 hours (beta), and 33 hours (gamma) [3]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.7524 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.25% [3]
Vd
The volume of distribution (Vd) of drug is 21 +/- 2 L/kg []
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Leukopenia rs6838440 ALPK1 OTBW6SGD [5]
Leukopenia rs2916733 MCPH1 OTYT3TT5 [5]
Neutropenia rs908366 LHPP OT9AGAIJ [6]
Neutropenia rs4149639 TNFRSF1A OT2D9DOV [6]
Neutropenia rs2964475 KIAA0947 OTOXTBUH [6]
Chemical Identifiers
Formula
C27H29NO11
IUPAC Name
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES
C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
InChI
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
InChIKey
AOJJSUZBOXZQNB-VTZDEGQISA-N
Cross-matching ID
PubChem CID
41867
ChEBI ID
CHEBI:47898
CAS Number
56420-45-2
UNII
3Z8479ZZ5X
DrugBank ID
DB00445
TTD ID
D0C9XJ
VARIDT ID
DR00170
INTEDE ID
DR0591
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-protein kinase 1 (ALPK1) OTBW6SGD ALPK1_HUMAN Drug Response [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [11]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [12]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Gene/Protein Processing [12]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [12]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Drug Response [13]
Baculoviral IAP repeat-containing protein 6 (BIRC6) OTCQJAB0 BIRC6_HUMAN Drug Response [14]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Drug Response [15]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [16]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 -1.4429 2.2902 -2.4931 20.4381
ES8 GDSC2 -5.4926 -2.1039 -5.5778 54.7233
ES7 GDSC2 -5.3033 -2.9735 -5.3174 53.1599
SK-PN-DW GDSC2 -4.7499 -2.7287 -4.7603 47.6863
EW-1 GDSC2 -4.5184 -0.9759 -4.703 45.7526
EW-16 GDSC2 -4.4878 -0.8038 -4.7039 45.525
HuO9 GDSC2 -4.4021 -1.4682 -4.4974 44.4558
EW-3 GDSC2 -4.3198 -1.6237 -4.3903 43.5853
EW-22 GDSC2 -4.2501 -1.4892 -4.3326 42.9381
SK-ES-1 GDSC2 -4.1875 -1.2767 -4.2952 42.4048
EW-12 GDSC2 -4.1667 -2.5022 -4.1668 74.8656
HOS GDSC2 -3.5159 -0.2901 -3.7618 36.387
TC-71 GDSC2 -3.2687 -1.408 -3.3037 32.9763
A-673 GDSC2 -3.1648 0.3776 -3.5639 33.6482
ES5 GDSC2 -3.0928 1.6664 -3.3061 61.612
EW-13 GDSC2 -3 1.6513 -3.8368 33.9393
ES1 GDSC2 -2.7652 0.5708 -3.1909 29.9019
ES4 GDSC2 -2.6439 -0.9452 -2.693 26.7814
EW-7 GDSC2 -2.6368 0.4702 -3.0185 28.4247
EW-11 GDSC2 -2.4902 0.2732 -2.7968 26.5884
MHH-ES-1 GDSC2 -2.4572 0.3295 -2.4835 43.5687
CADO-ES1 GDSC2 -2.2455 0.0831 -2.4738 23.7334
H-EMC-SS GDSC2 -1.984 1.635 -2.7578 24.1144
CAL-72 GDSC2 -1.9576 2.0458 -2.9061 24.792
EW-18 GDSC2 -1.942 1.7247 -2.7518 23.9036
CHSA8926 GDSC2 -1.6939 1.0684 -2.2202 19.896
SJSA-1 GDSC2 -1.5619 1.7461 -2.3685 20.1998
EW-24 GDSC2 -1.4473 0.451 -1.7221 16.0114
CAL-78 GDSC2 -1.3499 0.102 -1.5022 14.3548
NY GDSC2 -1.3386 5.3596 -3.8633 26.8977
HuO-3N1 GDSC2 -1.269 2.4107 -2.3766 19.1014
MG-63 GDSC2 -1.0862 7.6888 -4.7833 29.4794
U2OS GDSC2 -0.8556 0.9202 -0.8647 31.4753
CHSA0011 GDSC2 -0.8462 5.5059 -1.9659 44.3219
SaOS-2 GDSC2 -0.8311 3.1029 -2.2888 16.9943
NOS-1 [Human HNSCC] GDSC2 -0.5315 1.7459 -1.3476 10.2138
ES6 GDSC2 -0.4498 8.9533 -4.8568 27.6705
CHSA0108 GDSC2 -0.105 3.4491 -0.4535 35.9498
G-292 clone A141B1 GDSC2 0.0903 3.5167 -1.6837 10.3759
U-CH2 GDSC2 1.2517 8.5528 -1.1701 32.1297
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 162 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JM1 GDSC2 -3.8125 -1.5158 -3.8148 70.9294
SU-DHL-5 GDSC2 -8.0343 -5.9747 -8.0346 79.4979
MOLT-16 GDSC2 -7.4862 -6.6608 -7.4862 75.12
Farage GDSC2 -7.36 -3.1061 -7.3755 89.8772
697 GDSC2 -7.1817 -4.353 -7.1913 70.71
CESS GDSC2 -6.8274 -4.0002 -6.8401 67.4967
MOLM-13 GDSC2 -6.5931 -4.8635 -6.5935 66.0563
DoHH2 GDSC2 -6.5433 -3.5849 -6.545 90.1333
RCH-ACV GDSC2 -6.476 -3.9895 -6.4764 91.2612
KOPN-8 GDSC2 -6.4604 -4.4035 -6.4623 64.6207
SR GDSC2 -6.2369 -2.6434 -6.3075 61.3472
CTV-1 GDSC2 -6.1086 -3.8992 -6.1133 61.1083
ARH-77 GDSC2 -6.0558 -4.074 -6.058 60.6638
SUP-M2 GDSC2 -6.0353 -4.7907 -6.0353 60.5592
JSC-1 GDSC2 -6.0338 -1.9429 -6.1741 59.1316
IM-9 GDSC2 -6.008 -3.5282 -6.0189 60.0108
KE-37 GDSC2 -5.9711 -4.1898 -5.9721 59.8668
DEL GDSC2 -5.9553 -2.3935 -6.0355 58.853
MV4-11 GDSC2 -5.9283 -4.0052 -5.9303 59.4146
SU-DHL-16 GDSC2 -5.9247 0.2959 -6.1329 77.5386
JVM-3 GDSC2 -5.7729 -2.7779 -5.8119 57.5112
MOLT-4 GDSC2 -5.7564 -4.2953 -5.7566 57.7553
Namalwa GDSC2 -5.7351 -3.5132 -5.742 57.4333
A3/Kawakami GDSC2 -5.7297 -3.657 -5.734 57.414
NB4 GDSC2 -5.6818 -4.0093 -5.6818 88.4509
SU-DHL-1 GDSC2 -5.6759 -3.5962 -5.676 87.3746
Raji GDSC2 -5.5522 -3.579 -5.5559 55.6693
VAL GDSC2 -5.5336 -3.6415 -5.5364 55.4942
NALM-6 GDSC2 -5.5272 -3.9103 -5.528 55.4523
JVM-2 GDSC2 -5.4877 -1.0783 -5.7327 54.2818
BV-173 GDSC2 -5.478 -4.5212 -5.478 54.9722
BONNA-12 GDSC2 -5.4354 0.0964 -5.5861 76.476
L-428 GDSC2 -5.4115 -4.3249 -5.4116 54.305
SKM-1 GDSC2 -5.3644 -3.1916 -5.3647 84.763
ATN-1 GDSC2 -5.3447 -4.1408 -5.3448 53.6338
RL GDSC2 -5.3069 0.7562 -5.5388 74.4859
P12-Ichikawa GDSC2 -5.2515 -3.4301 -5.2545 52.6863
CML-T1 GDSC2 -5.1949 -4.0779 -5.195 52.1316
BL-41 GDSC2 -5.1904 -3.2907 -5.1946 52.0726
WIL2 NS GDSC2 -5.0616 -3.1178 -5.0674 50.7884
SCC-3 GDSC2 -5.0263 -3.1573 -5.0309 50.4367
RPMI-8402 GDSC2 -4.9253 -2.9158 -4.9337 49.4311
Jiyoye GDSC2 -4.9112 -3.0093 -4.9171 49.2888
TALL-1 [Human adult T-ALL] GDSC2 -4.8355 2.4001 -5.3468 69.46
MC116 GDSC2 -4.8351 0.2923 -4.9726 73.6815
RS4;11 GDSC2 -4.7961 -2.9769 -4.8012 48.1388
HC-1 GDSC2 -4.7437 -2.0311 -4.7956 47.6877
OCI-Ly19 GDSC2 -4.7218 -2.256 -4.7236 78.8597
SUP-B15 GDSC2 -4.7189 -3.4892 -4.7191 47.3554
CCRF-CEM GDSC2 -4.6904 -2.4787 -4.7093 47.1108
EB2 GDSC2 -4.68 -1.8854 -4.7426 47.0833
SUP-B8 GDSC2 -4.6069 -1.7503 -4.6127 77.1212
SU-DHL-4 GDSC2 -4.5986 -0.4581 -4.6541 74.2587
WSU-NHL GDSC2 -4.5708 -2.0014 -4.6168 45.9855
OCI-Ly7 GDSC2 -4.5463 -2.4374 -4.5469 77.9343
NU-DUL-1 GDSC2 -4.5261 -3.2654 -4.5261 78.6133
EoL-1 GDSC2 -4.4987 -1.9561 -4.5452 45.2777
MHH-CALL-4 GDSC2 -4.4766 -2.4766 -4.477 77.4525
CTB-1 GDSC2 -4.4659 -0.0545 -4.5472 72.6958
BALL-1 GDSC2 -4.4611 -2.6514 -4.4683 44.7935
OCI-M1 GDSC2 -4.3795 -2.4425 -4.3917 43.9948
P32/ISH GDSC2 -4.3751 -2.7419 -4.3792 43.9207
QIMR-WIL GDSC2 -4.3637 -2.0417 -4.3652 75.9726
ML-2 GDSC2 -4.3214 -2.4527 -4.3319 43.4069
MY-M12 GDSC2 -4.2604 -1.884 -4.2623 74.9616
A4/Fukuda GDSC2 -4.23 -1.8206 -4.2754 42.6199
AMO1 GDSC2 -4.2181 -2.6909 -4.2213 42.3433
CRO-AP2 GDSC2 -4.2064 -1.2842 -4.2157 73.6125
Reh GDSC2 -4.1871 -2.6533 -4.1906 42.0335
Daudi GDSC2 -4.1611 -1.6873 -4.2157 41.9695
RC-K8 GDSC2 -4.1384 -1.1932 -4.2554 41.9558
RPMI-8226 GDSC2 -4.0904 -1.6599 -4.1439 41.2648
PF-382 GDSC2 -4.0557 -1.429 -4.1335 41.0106
Karpas-1106P GDSC2 -4.0385 -0.5217 -4.2767 41.375
Jurkat GDSC2 -4.025 -2.8315 -4.0256 40.3943
BC-1 GDSC2 -4.0067 -1.3379 -4.0932 40.5592
TUR GDSC2 -3.9733 -2.3047 -3.9814 39.9101
Hs 445 GDSC2 -3.9698 -1.1127 -4.0871 40.31
LC4-1 GDSC2 -3.9516 -1.8089 -3.9849 39.803
SU-DHL-10 GDSC2 -3.9472 -1.9995 -3.9676 39.7038
SUP-HD1 GDSC2 -3.9405 -0.0277 -4.2928 40.8018
Granta-519 GDSC2 -3.9229 -0.9801 -4.0589 39.9194
EM-2 GDSC2 -3.9213 -2.7598 -3.9219 39.3535
THP-1 GDSC2 -3.8822 -2.951 -3.8822 72.2874
KM-H2 GDSC2 -3.8789 -0.1518 -4.1927 40.1083
ALL-SIL GDSC2 -3.8698 -1.756 -3.9037 38.9884
HL-60 GDSC2 -3.8538 -1.6983 -3.8916 38.8453
H9 GDSC2 -3.826 -1.4054 -3.8923 38.6901
NCI-H929 GDSC2 -3.7935 -2.0329 -3.8075 38.1353
OCI-AML-3 GDSC2 -3.7811 -1.6466 -3.82 38.1241
MHH-CALL-2 GDSC2 -3.7707 -1.8589 -3.7933 37.9464
SU-DHL-8 GDSC2 -3.7319 -1.2837 -3.8075 37.7945
P30/OHK GDSC2 -3.6853 -1.9587 -3.6996 37.0516
BC-3 GDSC2 -3.6853 -1.0249 -3.6927 69.3424
ALL-PO GDSC2 -3.6741 -1.4196 -3.7297 37.1305
OCI-AML-2 GDSC2 -3.6713 -1.8254 -3.6923 36.943
Karpas-299 GDSC2 -3.6176 -1.4644 -3.6653 36.5299
L-540 GDSC2 -3.553 -0.541 -3.7443 36.5205
NKM-1 GDSC2 -3.5038 -1.4167 -3.5502 35.3862
RPMI-6666 GDSC2 -3.4554 -1.0481 -3.5452 35.1065
MLMA GDSC2 -3.3519 0.6581 -3.8568 35.8625
MOLP-8 GDSC2 -3.3364 -1.4243 -3.3733 33.664
MHH-PREB-1 GDSC2 -3.3222 -1.6002 -3.3445 33.45
DB GDSC2 -3.2974 -0.4792 -3.4799 33.9674
Karpas-422 GDSC2 -3.2681 -0.6989 -3.4029 33.4534
VL51 GDSC2 -3.1968 -0.7494 -3.3164 32.6706
MOLT-13 GDSC2 -3.1835 -1.4871 -3.2081 32.0703
YT GDSC2 -3.1605 -1.1949 -3.2113 31.9703
DND-41 GDSC2 -3.0227 -1.3742 -3.0489 30.4652
NOMO-1 GDSC2 -2.9576 -1.5867 -2.9684 29.7344
GDM-1 GDSC2 -2.9322 -0.4764 -3.0837 30.19
KY821 GDSC2 -2.9158 -1.5422 -2.9275 29.3191
HEL GDSC2 -2.8886 -0.7946 -2.8915 62.1535
KMS-12-BM GDSC2 -2.8566 -0.3924 -3.0198 29.4952
WSU-DLCL2 GDSC2 -2.8459 1.2351 -3.5129 31.8051
Karpas-231 GDSC2 -2.791 -1.5629 -2.7986 28.0463
DG-75 GDSC2 -2.6991 0.662 -3.1498 29.3808
BE-13 GDSC2 -2.6846 -0.213 -2.8745 27.9161
HT GDSC2 -2.6448 3.822 -3.3329 56.7742
GA-10 GDSC2 -2.575 1.8575 -3.4695 30.3093
MN-60 GDSC2 -2.5514 0.0764 -2.8057 26.923
CA46 GDSC2 -2.528 2.0543 -3.5018 30.2366
MM1.S GDSC2 -2.5005 0.3035 -2.8174 26.744
KCL-22 GDSC2 -2.414 1.1507 -3.0187 27.3855
Kasumi-1 GDSC2 -2.3369 1.049 -2.4133 56.2574
SUP-T1 GDSC2 -2.3245 3.2948 -3.8362 30.7543
PL-21 GDSC2 -2.3235 -0.5439 -2.3251 56.6213
Loucy GDSC2 -2.2433 0.5861 -2.63 24.5652
P31/FUJ GDSC2 -2.1457 -1.2981 -2.1486 21.5469
Mono-Mac-6 GDSC2 -2.0969 0.2649 -2.3658 22.4689
OPM-2 GDSC2 -2.0391 0.9996 -2.5604 23.278
MEG-01 GDSC2 -2.0308 0.5196 -2.3771 22.2333
HAL-01 GDSC2 -2.0302 -0.428 -2.1151 20.8113
MOLM-16 GDSC2 -1.9888 -0.2694 -1.9906 53.282
ST486 GDSC2 -1.9465 -0.0337 -2.1151 20.4192
JJN-3 GDSC2 -1.9445 -0.3252 -2.0429 20.0235
L-363 GDSC2 -1.8865 -0.7957 -1.9082 19.0414
Ku812 GDSC2 -1.8843 0.123 -2.0912 20.0047
U-698-M GDSC2 -1.8001 -0.1956 -1.9148 18.662
NK-92MI GDSC2 -1.6887 0.45 -1.6999 50.2783
SU-DHL-6 GDSC2 -1.6555 0.0511 -1.8209 17.4869
KMOE-2 GDSC2 -1.6553 0.2318 -1.8747 17.7811
LAMA-84 GDSC2 -1.6434 0.837 -2.0755 18.8588
Ramos.2G6.4C10 GDSC2 -1.5784 0.1474 -1.765 16.8307
L-1236 GDSC2 -1.4407 1.8267 -2.2805 19.2103
KMS-11 GDSC2 -1.4138 1.2242 -1.4594 47.6004
JeKo-1 GDSC2 -1.2324 1.9198 -1.3476 45.9652
GR-ST GDSC2 -1.1594 2.7308 -2.4209 18.9459
TK [Human B-cell lymphoma] GDSC2 -1.0683 0.6159 -1.3772 12.4255
U266B1 GDSC2 -1.0439 1.1621 -1.5808 13.524
Karpas-45 GDSC2 -0.9697 2.4144 -2.087 16.2876
EJM GDSC2 -0.873 1.3395 -1.4873 12.3046
K-562 GDSC2 -0.7659 1.0516 -1.2486 10.4563
KG-1 GDSC2 -0.7181 0.8535 -1.1113 9.4472
SIG-M5 GDSC2 -0.6993 2.8797 -0.9542 41.2629
Karpas-620 GDSC2 -0.2468 2.1699 -1.2969 8.9565
ME1 GDSC2 0.1259 2.5334 -1.1633 7.0066
HDLM-2 GDSC2 0.2687 3.1501 -1.3571 7.8374
SK-MM-2 GDSC2 0.5373 2.5282 -0.8491 4.0001
LP-1 GDSC2 1.4391 3.6063 1.183 20.2599
ROS-50 GDSC2 1.9892 10.9151 -1.6354 30.8902
HH [Human lymphoma] GDSC2 2.0557 4.3581 -0.7976 1.3835
⏷ Show the Full List of 162 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-220 GDSC2 -3.6205 -0.1117 -3.9213 37.6135
HCE-4 GDSC2 -2.5424 1.5238 -2.6918 57.6916
OACM5.1 C GDSC2 -2.4732 0.6174 -2.8897 26.9944
FLO-1 GDSC2 -2.1066 2.1779 -3.117 26.5146
OACP4 C GDSC2 -2.0858 0.3818 -2.3909 22.5557
KYAE-1 GDSC2 -1.9209 0.8829 -2.3896 21.8196
ESO-51 GDSC2 -1.717 1.4486 -2.4008 21.0176
ESO-26 GDSC2 -1.4749 0.5051 -1.7712 16.4082
KYSE-50 GDSC2 -0.1783 2.2062 -1.255 8.4788
SK-GT-4 GDSC2 0.3589 5.7349 -2.5741 14.9252
TE-12 GDSC2 0.8046 9.2594 -1.9383 36.2196
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 -1.08 4.2947 -3.1026 22.3864
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CHP-134 GDSC2 -6.8115 -4.6478 -6.8134 67.9699
IMR-5 GDSC2 -6.5328 -4.8743 -6.5331 65.4788
NB69 GDSC2 -4.7099 -0.3345 -5.0527 47.6792
SJNB-17 GDSC2 -4.1882 -0.225 -4.2435 71.5129
CHP-126 GDSC2 -4.184 8.327 -6.6249 60.283
MHH-NB-11 GDSC2 -3.8975 -0.2249 -3.9414 69.7028
Kelly GDSC2 -3.8293 0.2123 -4.2389 39.9509
SK-N-MC-IXC GDSC2 -3.6529 -2.0285 -3.653 69.8646
SJNB-13 GDSC2 -3.5327 -0.1204 -3.8231 36.7306
SJNB-14 GDSC2 -3.3562 -0.4628 -3.5475 34.5871
SJNB-10 GDSC2 -3.333 -0.378 -3.5416 34.4371
GI-ME-N GDSC2 -3.0846 2.2132 -4.1513 35.5381
CHP-212 GDSC2 -2.9988 1.63 -3.8272 33.8951
NH-12 GDSC2 -2.8756 0.4585 -3.2744 30.8472
SiMa GDSC2 -2.8431 -0.285 -3.0299 29.4798
GOTO GDSC2 -2.7894 1.2297 -3.4504 31.247
SK-N-DZ GDSC2 -2.6323 2.0817 -3.6223 31.2564
KP-N-YN GDSC2 -2.2993 3.4109 -3.8636 30.7555
NB1 GDSC2 -2.1229 -0.1395 -2.2802 22.1255
SJNB-7 GDSC2 -1.5502 2.8053 -2.838 22.7664
SK-N-AS GDSC2 -1.2303 1.5592 -1.9472 16.4312
KP-N-YS GDSC2 -1.2087 3.8604 -1.7794 46.4074
SJNB-5 GDSC2 -1.0751 2.6015 -1.3009 44.7038
SK-N-BE(2)-M17 GDSC2 -0.969 1.5573 -1.6831 13.85
SK-N-SH GDSC2 -0.9247 3.3668 -2.5048 18.5786
NB(TU)1 GDSC2 -0.667 3.4415 -2.304 16.5205
LA-N-6 GDSC2 -0.271 3.4686 -0.6401 37.6081
SJNB-12 GDSC2 -0.1719 6.3117 -3.3002 20.3476
KP-N-RT-BM-1 GDSC2 -0.1337 8.2374 -2.3888 41.2787
SK-N-FI GDSC2 0.3378 6.5958 -3.0208 17.4092
TGW GDSC2 0.6603 6.0646 -2.5011 13.691
SJNB-6 GDSC2 3.4743 6.7612 1.7276 9.6427
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 -1.5339 1.2585 -2.1298 18.7131
Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC2 -5.4629 -2.6324 -5.4995 54.619
CAL-148 GDSC2 -4.4393 -0.0663 -4.8268 45.381
CAL-51 GDSC2 -3.9831 -0.5742 -4.2046 40.7958
AU565 GDSC2 -2.4989 3.8938 -4.2845 33.2284
HCC1806 GDSC2 -2.4298 1.7199 -3.2605 28.6583
HCC1599 GDSC2 -2.3811 0.3806 -2.4077 56.9467
MDA-MB-231 GDSC2 -2.2602 1.5057 -2.9946 26.5668
CAL-120 GDSC2 -1.7588 2.1761 -2.76 23.1832
HCC2157 GDSC2 -1.6983 0.6242 -2.0548 18.9774
OCUB-M GDSC2 -1.5197 0.4288 -1.7926 16.7241
BT-549 GDSC2 -1.4111 1.285 -2.0131 17.5367
MDA-MB-468 GDSC2 -1.2712 6.1349 -4.1821 27.9497
CAMA-1 GDSC2 -1.2252 2.8949 -2.5626 20.0003
Evsa-T GDSC2 -1.1868 0.9833 -1.6519 14.5143
HDQ-P1 GDSC2 -1.1536 4.1987 -3.1241 22.7629
T-47D GDSC2 -1.0245 2.453 -2.1582 16.9112
MDA-MB-453 GDSC2 -0.984 0.3525 -1.1872 10.9789
HCC1500 GDSC2 -0.8196 1.159 -1.3514 11.2809
MDA-MB-157 GDSC2 -0.7762 0.9433 -1.2104 10.2661
MRK-nu-1 GDSC2 -0.7294 1.6244 -1.4785 11.7205
MDA-MB-175-VII GDSC2 -0.6942 0.8106 -1.0679 9.0942
HCC38 GDSC2 -0.6792 4.4942 -2.8355 19.5767
HCC70 GDSC2 -0.601 2.1499 -1.6094 12.0759
Hs 578T GDSC2 -0.4825 6.5047 -3.6626 23.0538
UACC-812 GDSC2 -0.3201 4.3305 -2.4374 16.1671
EFM-19 GDSC2 -0.2982 3.5405 -2.0245 13.6428
MCF-7 GDSC2 -0.2431 2.6121 -1.5138 10.3084
HCC2218 GDSC2 -0.1239 1.6906 -0.1489 34.7024
MDA-MB-415 GDSC2 -0.0216 2.0715 -1.0538 6.7347
YMB-1-E GDSC2 0.0341 9.6375 -2.8682 41.3158
HCC1569 GDSC2 0.063 5.867 -1.1493 37.4636
UACC-893 GDSC2 0.163 3.2381 -0.1029 32.9895
COLO 824 GDSC2 0.3199 5.1504 -2.3137 13.5408
BT-474 GDSC2 0.3685 3.4676 -1.4371 8.0731
BT-20 GDSC2 0.4166 3.9239 -1.6265 9.1253
HCC1937 GDSC2 0.4288 3.8429 -1.5769 8.7854
HCC1419 GDSC2 0.4488 3.9101 -1.5948 8.844
CAL-85-1 GDSC2 0.4868 5.1033 -2.1581 12.1677
JIMT-1 GDSC2 0.5184 3.3588 -1.2694 6.6463
MDA-MB-330 GDSC2 0.5498 2.8543 0.4103 28.531
MFM-223 GDSC2 0.5612 2.5472 -0.8417 3.9018
MDA-MB-361 GDSC2 0.5767 2.675 -0.8927 4.1791
HCC1954 GDSC2 0.5812 2.5561 -0.8321 3.7992
EFM-192A GDSC2 0.5868 2.9446 -1.0165 4.9168
MDA-MB-436 GDSC2 0.6399 6.0177 -2.4936 13.7026
HCC1143 GDSC2 0.6946 2.9946 -0.9654 4.3631
HCC1428 GDSC2 0.8781 3.7498 -1.2032 5.4085
ZR-75-30 GDSC2 0.9455 3.9969 -1.2759 5.7028
HCC1187 GDSC2 1.738 3.4205 -0.5694 0.7557
HCC1395 GDSC2 1.7496 8.8141 -3.0477 13.9321
BT-483 GDSC2 1.9325 7.8574 -2.4582 10.4352
⏷ Show the Full List of 51 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med GDSC2 -4.873 -0.225 -5.2584 49.0918
H4 GDSC2 -4.0929 0.0853 -4.4903 42.3194
M059J GDSC2 -4.0836 -0.8597 -4.2547 41.5981
A-172 GDSC2 -3.8893 0.4325 -4.3701 40.7097
8-MG-BA GDSC2 -3.8265 -1.253 -3.9126 38.7771
42-MG-BA GDSC2 -3.4816 0.1715 -3.8478 36.5418
D-423MG GDSC2 -3.3019 1.6236 -3.524 63.0428
AM-38 GDSC2 -2.8291 0.237 -3.1553 30.0382
Daoy GDSC2 -2.8032 0.1727 -3.1081 29.6776
U-251MG GDSC2 -2.7555 0.0842 -3.0306 29.0566
GaMG GDSC2 -2.6986 2.2523 -3.763 32.165
PFSK-1 GDSC2 -2.6102 0.7543 -3.0852 28.6356
SF539 GDSC2 -2.2499 2.4377 -3.3778 28.409
D-336MG GDSC2 -2.2469 2.2405 -2.4981 54.9299
D-566MG GDSC2 -2.1366 0.9464 -2.1928 54.5053
SF295 GDSC2 -1.8943 3.0083 -2.2882 51.8903
LN-18 GDSC2 -1.7418 2.6856 -2.9733 24.2491
GI-1 GDSC2 -1.6475 0.6007 -1.9915 18.4003
D-392MG GDSC2 -1.6472 0.858 -2.0877 18.9447
SNB-75 GDSC2 -1.5712 3.041 -1.9441 49.2561
D-263MG GDSC2 -1.5514 2.3874 -2.6461 21.7234
MOG-G-UVW GDSC2 -1.5323 0.8741 -1.9718 17.7967
U-87MG ATCC GDSC2 -1.5022 3.7668 -3.2457 24.6835
SW1783 GDSC2 -1.4787 2.3514 -2.557 20.9392
KALS-1 GDSC2 -1.4711 1.5628 -2.195 18.8358
SF126 GDSC2 -1.3867 2.3241 -1.5827 47.5256
Becker GDSC2 -1.369 2.4864 -2.5105 20.2504
Hs 683 GDSC2 -1.2573 3.5223 -1.7316 46.7002
SK-MG-1 GDSC2 -1.203 2.8281 -2.5093 19.6149
ONS-76 GDSC2 -1.1984 1.7973 -2.0227 16.7558
KS-1 [Human Krukenberg tumour] GDSC2 -1.1958 0.9738 -1.6573 14.5826
LN-229 GDSC2 -1.1556 0.7502 -1.5232 13.6347
YKG-1 GDSC2 -1.1505 1.6269 -1.222 45.0815
DBTRG-05MG GDSC2 -1.1452 4.5784 -3.3019 23.622
SF268 GDSC2 -1.0115 2.5054 -2.1707 16.938
GB-1 GDSC2 -0.7193 2.4876 -1.8844 14.1751
SW1088 GDSC2 -0.7022 4.2663 -2.7433 19.15
U-118MG GDSC2 -0.6936 2.8297 -2.0276 14.9582
Onda 10 GDSC2 -0.6123 1.8574 -0.6782 39.7637
DK-MG GDSC2 -0.5187 0.8544 -0.9106 7.4751
YH-13 GDSC2 -0.5179 4.4688 -2.6794 18.181
CAS-1 GDSC2 -0.3584 1.9194 -1.2727 9.1632
D-542MG GDSC2 -0.3207 2.3914 -0.4435 37.1116
KINGS-1 GDSC2 -0.2392 4.4511 -2.4279 15.858
MOG-G-CCM GDSC2 -0.0963 3.0744 -1.6182 10.5135
D-247MG GDSC2 -0.0146 6.5472 -1.518 38.8742
KNS-42 GDSC2 0.1883 6.9125 -1.4684 37.7407
D-502MG GDSC2 0.6244 10.6406 -2.7723 38.7601
LN-405 GDSC2 0.6426 2.6846 -0.8519 3.7868
T98G GDSC2 0.9428 4.2198 -1.3852 6.3687
Onda 11 GDSC2 1.0047 5.0446 0.1786 27.5742
D-245MG GDSC2 1.1889 11.2157 -2.5183 36.1148
NMC-G1 GDSC2 2.1364 6.931 0.4542 21.5369
KNS-81-FD GDSC2 2.1767 8.4411 -0.2452 24.8821
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC2 -0.8355 3.5906 -2.5316 18.4195
TGBC1TKB GDSC2 0.1698 6.8534 -3.2863 19.247
TGBC24TKB GDSC2 0.8194 3.4344 -1.0916 4.8598
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ESS-1 GDSC2 -4.715 -3.0461 -4.7181 47.3234
AN3-CA GDSC2 -1.2804 2.6377 -2.4944 19.8209
RL95-2 GDSC2 -0.8774 2.9847 -2.2745 17.0729
MFE-319 GDSC2 -0.5186 2.7194 -1.8129 13.0567
EN GDSC2 -0.5115 1.7757 -1.3434 10.1184
MFE-280 GDSC2 -0.4631 3.521 -2.1599 14.9876
KLE GDSC2 0.1765 6.632 -3.1701 18.6443
MFE-296 GDSC2 0.3826 3.1458 -1.2665 6.9697
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ACHN GDSC2 -3.8621 -1.5249 -3.917 39.001
786-O GDSC2 -3.1018 0.9624 -3.6893 33.8592
LB996-RCC GDSC2 -2.9385 2.9746 -4.3205 35.3886
BFTC-909 GDSC2 -2.536 1.6048 -3.326 29.4617
769-P GDSC2 -2.484 2.2393 -3.534 30.178
SW13 GDSC2 -2.385 2.3138 -3.4632 29.4073
CAL-54 GDSC2 -2.2457 1.9299 -3.1549 27.3124
KTCTL-195 GDSC2 -1.3142 0.888 -1.7463 15.5864
SN12C GDSC2 -0.9083 3.1098 -2.3643 17.7084
KTCTL-140 GDSC2 -0.804 3.6002 -1.2598 42.7573
Caki-1 GDSC2 -0.7828 3.4935 -1.2057 42.4894
TK-10 GDSC2 -0.7286 3.2848 -2.2831 16.6072
KMRC-20 GDSC2 -0.6762 3.4197 -2.3016 16.5379
KMRC-1 GDSC2 -0.5757 2.7125 -1.8615 13.546
LB2241-RCC GDSC2 -0.5033 1.6864 -0.5453 38.5785
KTCTL-21 GDSC2 -0.4579 2.2489 -0.5674 38.411
A-498 GDSC2 -0.3939 4.8457 -2.7585 18.2168
SW156 GDSC2 -0.2158 3.8289 -0.6883 37.4697
KTCTL-13 GDSC2 -0.0763 4.0118 -0.5957 36.3493
NCC010 GDSC2 -0.0304 3.5085 -0.3892 35.2768
RCC10RGB GDSC2 -0.0268 1.9811 -1.013 6.4917
OS-RC-2 GDSC2 0.3039 4.0569 -1.7811 10.382
HA7-RCC GDSC2 0.3039 2.8604 0.1418 31.0981
A-704 GDSC2 0.3445 2.594 -1.0223 5.537
UO-31 GDSC2 0.4053 2.8473 0.2548 30.03
RXF 393L GDSC2 0.5373 3.6315 0.1932 29.69
BB65-RCC GDSC2 0.7217 4.752 -0.0031 29.7578
LB1047-RCC GDSC2 0.7821 3.9273 0.3641 27.6574
KTCTL-1M GDSC2 0.8266 5.0778 -0.0222 29.3588
KTCTL-26A GDSC2 0.9846 4.0321 0.5472 25.7656
VMRC-RCZ GDSC2 1.1013 5.6881 -1.9867 9.6114
NCC021 GDSC2 2.165 5.2648 1.2738 16.7487
VMRC-RCW GDSC2 2.9238 5.3614 1.954 9.8909
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDST8 GDSC2 -3.6077 0.9315 -4.2258 38.6021
KM12 GDSC2 -3.239 -0.38 -3.4388 33.4705
SNU-175 GDSC2 -3.1307 -0.295 -3.3408 32.4492
HCT 116 GDSC2 -3.1115 0.4187 -3.5186 33.171
HCC2998 GDSC2 -2.8658 0.1012 -3.1558 30.2213
COLO 320HSR GDSC2 -2.8217 3.0771 -4.2449 34.5722
SNU-C5 GDSC2 -2.7508 0.5465 -3.1673 29.7166
COLO205 GDSC2 -2.6048 1.5931 -3.3942 30.1039
SW48 GDSC2 -2.5655 0.7986 -3.0524 28.2593
GP5d GDSC2 -2.5535 1.0358 -3.1252 28.5682
RKO GDSC2 -2.3659 0.6056 -2.7695 25.8687
SK-CO-1 GDSC2 -2.119 0.3342 -2.4118 22.8196
NCI-H508 GDSC2 -1.9915 3.3376 -2.4811 52.5647
LS123 GDSC2 -1.8264 1.4411 -2.512 22.0986
SW620 GDSC2 -1.6986 2.4583 -1.9478 38.5749
LoVo GDSC2 -1.4721 1.3826 -2.118 18.3932
HCT 15 GDSC2 -1.3242 2.896 -2.6591 20.9147
HT-55 GDSC2 -1.0106 1.4669 -1.6835 14.0103
HT-29 GDSC2 -1.0028 1.1596 -1.0268 32.6386
SNU-407 GDSC2 -1.0017 2.7067 -2.2578 17.418
LS411N GDSC2 -0.9745 3.0606 -2.4027 18.1672
SNU-81 GDSC2 -0.7688 3.524 -1.1992 42.3829
COLO 678 GDSC2 -0.7615 1.6319 -1.5133 12.0501
LS180 GDSC2 -0.5837 5.7603 -3.3799 22.0564
SNU-283 GDSC2 -0.4602 2.4013 -0.5956 38.5385
CaR-1 GDSC2 -0.4578 2.5225 -1.6605 11.9125
NCI-H747 GDSC2 -0.3481 3.8692 -2.2318 15.0482
SW837 GDSC2 -0.2366 2.6687 -1.5363 10.4291
SW626 GDSC2 -0.1153 2.3261 -1.2604 8.3205
RCM-1 [Human ESC] GDSC2 -0.0122 2.217 -1.1186 7.1175
SNU-C2B GDSC2 0.2095 4.2119 -1.934 11.5811
C2BBe1 GDSC2 0.2285 3.9361 -1.7811 10.5896
SW1417 GDSC2 0.2821 2.7682 -1.1566 6.5415
SW1463 GDSC2 0.3645 4.4184 -1.9132 11.0263
CCK-81 GDSC2 0.4465 3.7013 -1.493 8.2185
DiFi GDSC2 0.5338 4.3379 -1.7417 9.5294
HT115 GDSC2 0.7308 5.0963 -0.1307 30.3082
SW948 GDSC2 0.7728 6.5396 -2.6502 14.2262
CW-2 GDSC2 0.7804 4.2285 -1.5044 7.4648
SW1116 GDSC2 1.0502 6.441 -2.3927 12.0813
LS1034 GDSC2 1.0973 3.7256 -1.047 4.034
SNU-61 GDSC2 1.107 2.9938 -0.706 2.0969
NCI-H716 GDSC2 1.1565 4.8776 -1.5553 6.9253
T84 GDSC2 1.328 6.4406 -2.1918 10.278
CL-11 GDSC2 1.4154 7.5011 -2.6463 12.6083
SNU-C1 GDSC2 1.73 3.5431 -0.6212 0.9598
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 -2.9305 -0.4843 -3.0802 30.1641
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-398 GDSC2 -2.3639 0.981 -2.9013 26.5519
HLE GDSC2 -2.3595 1.4147 -3.0633 27.3636
SNU-423 GDSC2 -1.8306 2.7464 -3.0901 25.2143
SK-HEP-1 GDSC2 -1.6312 0.1455 -1.8219 17.3818
Hep 3B2.1-7 GDSC2 -1.0551 0.7041 -1.0618 43.9503
JHH-2 GDSC2 -0.4726 5.9954 -3.4001 21.7902
JHH-4 GDSC2 -0.2113 7.5553 -3.9551 23.4847
JHH-1 GDSC2 -0.042 1.653 -0.8618 5.5797
SNU-387 GDSC2 0.0244 3.0081 -1.4837 9.3148
Huh-7 GDSC2 0.271 2.3997 -0.9821 5.4734
Hep-G2/C3A GDSC2 0.3637 3.1499 -1.2831 7.1222
JHH-6 GDSC2 0.7701 8.3428 -3.5483 18.8222
HuH-1 GDSC2 0.781 3.4021 -1.1023 5.0074
JHH-7 GDSC2 0.8403 5.3155 -1.9941 10.2814
SNU-449 GDSC2 1.7273 4.3307 -0.9517 2.4873
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 182 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2110 GDSC2 -5.6899 -2.245 -5.6999 83.6461
Lu-134-A GDSC2 -5.4675 4.9088 -6.7462 67.7358
NCI-H1876 GDSC2 -5.0009 -2.6274 -5.0218 50.1806
EMC-BAC-2 GDSC2 -4.5772 -0.2692 -4.9244 46.53
SBC-3 GDSC2 -4.4578 -1.012 -4.6307 45.1627
A-427 GDSC2 -4.1837 0.6528 -4.3246 69.786
NCI-H209 GDSC2 -4.116 -2.3802 -4.1246 41.3429
NCI-H460 GDSC2 -3.8422 0.2368 -3.9189 68.5588
NCI-H1975 GDSC2 -3.8068 0.3322 -4.2497 39.8487
NCI-H211 GDSC2 -3.7953 -1.0097 -3.9163 38.6103
NCI-H2373 GDSC2 -3.6314 0.5264 -4.1183 38.3846
NCI-H1781 GDSC2 -3.6143 -0.4826 -3.8238 37.1944
NCI-H1734 GDSC2 -3.5192 -1.2783 -3.5217 68.1966
NCI-H292 GDSC2 -3.5178 1.3418 -3.71 64.7878
HCC78 GDSC2 -3.4231 0.0985 -3.7631 35.8779
NCI-H1155 GDSC2 -3.2757 -1.1618 -3.3376 33.1781
NCI-H1993 GDSC2 -3.2755 -1.3033 -3.321 33.0962
NCI-H1048 GDSC2 -2.9993 1.2439 -3.6808 33.2995
NCI-H1694 GDSC2 -2.9387 0.7584 -3.4421 31.9468
SBC-5 GDSC2 -2.8629 -0.2087 -3.0699 29.7789
NCI-H2227 GDSC2 -2.7374 6.648 -4.4239 55.6515
ABC-1 GDSC2 -2.6769 0.6819 -2.7361 59.394
NCI-H2795 GDSC2 -2.6758 1.1565 -3.3012 30.0041
HARA [Human squamous cell lung carcinoma] GDSC2 -2.6135 1.0147 -3.1819 29.1308
HCC44 GDSC2 -2.5651 1.0104 -3.1282 28.6374
NCI-H1651 GDSC2 -2.556 2.0446 -3.527 30.4801
DMS 79 GDSC2 -2.5334 4.3753 -3.384 55.7574
LOU-NH91 GDSC2 -2.4625 1.6042 -3.248 28.7479
NCI-H1703 GDSC2 -2.4601 0.3619 -2.7916 26.4204
NCI-H2810 GDSC2 -2.4595 2.0624 -2.6937 56.6842
COR-L303 GDSC2 -2.4366 2.4987 -2.7584 56.2369
NCI-H2722 GDSC2 -2.4187 0.2193 -2.7026 25.7581
NCI-H3122 GDSC2 -2.3759 0.5729 -2.7692 25.9127
NCI-H358 GDSC2 -2.3756 1.2037 -2.9979 27.1041
A-549 GDSC2 -2.3124 1.631 -3.1006 27.3392
COLO 668 GDSC2 -2.2961 0.5385 -2.6711 25.0253
CPC-N GDSC2 -2.266 0.4001 -2.5927 24.4674
COR-L279 GDSC2 -2.2411 6.3923 -5.2133 34.99
RERF-LC-KJ GDSC2 -2.1399 -1.1837 -2.1463 21.5064
Lu-65 GDSC2 -2.124 1.2866 -2.7627 24.7471
NCI-H322M GDSC2 -2.0986 2.2158 -3.1252 26.5212
EPLC-272H GDSC2 -2.0836 2.9681 -3.4452 28.0013
NCI-H2023 GDSC2 -2.0719 2.8203 -3.3666 27.5833
Lu-135 GDSC2 -2.0557 1.856 -2.9258 25.3139
NCI-H1666 GDSC2 -1.9995 1.6258 -2.7701 24.2469
NCI-H82 GDSC2 -1.9292 0.8342 -2.3802 21.8035
COR-L23 GDSC2 -1.9228 0.6939 -2.3217 21.4498
NCI-H1437 GDSC2 -1.8979 1.2168 -1.9676 52.2437
NCI-H1299 GDSC2 -1.8711 2.4707 -3.0059 24.95
LC-2/ad GDSC2 -1.8697 3.3683 -2.3565 51.6359
NCI-H1650 GDSC2 -1.8131 0.3759 -2.0928 19.6937
EBC-1 GDSC2 -1.8083 2.9751 -3.1728 25.539
NCI-H446 GDSC2 -1.7897 5.4113 -4.3112 30.3792
NCI-H2818 GDSC2 -1.7608 1.56 -2.4935 21.7211
COR-L311 GDSC2 -1.7531 4.0626 -3.6289 27.4706
SW1573 GDSC2 -1.7441 2.2816 -2.7922 23.2975
Lu-99A GDSC2 -1.7249 2.3378 -2.7981 23.2508
NCI-H23 GDSC2 -1.7034 2.753 -2.9659 24.0557
NCI-H1581 GDSC2 -1.6824 0.7706 -2.092 19.1188
HOP-62 GDSC2 -1.6506 1.5684 -2.3826 20.6406
RERF-LC-MS GDSC2 -1.5744 2.0591 -1.7373 49.2163
NCI-H1623 GDSC2 -1.5481 2.4244 -2.6599 21.7867
NCI-H810 GDSC2 -1.5116 2.5998 -2.7044 21.8879
LC-1/sq GDSC2 -1.487 1.1031 -2.0161 17.8633
LXF 289 GDSC2 -1.4482 2.4642 -2.5786 20.941
NCI-H2731 GDSC2 -1.4473 2.1859 -2.4498 20.2089
NCI-H647 GDSC2 -1.4096 2.7739 -1.7031 47.8251
LK-2 GDSC2 -1.4045 2.01 -2.3266 19.3343
NCI-H847 GDSC2 -1.363 0.8104 -1.7669 15.9082
NCI-H748 GDSC2 -1.3536 4.0116 -1.9844 47.6296
COR-L32 GDSC2 -1.3299 5.4556 -2.4634 38.2882
EMC-BAC-1 GDSC2 -1.2883 2.0486 -1.4276 46.5368
NCI-H838 GDSC2 -1.2513 1.0993 -1.2807 45.9723
NCI-H2171 GDSC2 -1.236 1.8665 -1.3437 45.9851
DMS 114 GDSC2 -1.2079 1.1768 -1.7562 15.2129
NCI-H513 GDSC2 -1.1238 3.935 -2.9678 21.8438
NCI-H650 GDSC2 -1.1084 2.6423 -2.3295 18.2275
NCI-H69 GDSC2 -1.0893 2.8186 -2.3953 18.5403
Ms-1 GDSC2 -1.0261 1.2805 -1.6151 13.6598
NCI-H524 GDSC2 -1.0037 1.9144 -1.8833 15.1878
NCI-H2461 GDSC2 -0.9823 4.8747 -3.2977 23.0174
KNS-62 GDSC2 -0.9742 2.4448 -2.1058 16.4162
SBC-1 GDSC2 -0.9639 2.8502 -1.2355 43.7759
NCI-H1792 GDSC2 -0.9353 2.816 -2.2473 17.1174
NCI-H290 GDSC2 -0.9051 2.2986 -1.0575 42.9204
COR-L105 GDSC2 -0.8658 4.6868 -3.099 21.6094
NCI-H2009 GDSC2 -0.8449 2.6816 -2.0967 15.8997
PC-14 GDSC2 -0.8411 2.2919 -0.9872 31.8778
NCI-H1688 GDSC2 -0.8088 1.4474 -1.4732 11.9787
NCI-H661 GDSC2 -0.7728 1.8784 -1.6414 12.8753
NCI-H2081 GDSC2 -0.7522 7.345 -2.6245 44.6493
NCI-H226 GDSC2 -0.7356 0.7248 -1.0729 9.2866
LCLC-97TM1 GDSC2 -0.7238 1.7998 -1.5566 12.18
LB647-SCLC GDSC2 -0.7032 3.4561 -1.1082 41.7268
IST-SL1 GDSC2 -0.6965 2.2458 -0.8235 40.8202
DMS 53 GDSC2 -0.687 2.0166 -1.6257 12.4746
HOP-92 GDSC2 -0.6388 3.3201 -2.2184 15.9185
ChaGo-K-1 GDSC2 -0.6385 1.9857 -0.7222 40.0919
SHP-77 GDSC2 -0.5898 2.2258 -1.6359 12.2018
NCI-H1568 GDSC2 -0.5776 1.0609 -1.0647 8.6325
RERF-LC-Sq1 GDSC2 -0.5672 3.3344 -2.1607 15.3347
UMC-11 GDSC2 -0.567 5.0036 -2.9887 20.0213
NCI-H1105 GDSC2 -0.5632 2.8057 -0.789 39.8733
NCI-H2228 GDSC2 -0.5556 5.2584 -3.1055 20.592
NCI-H1563 GDSC2 -0.5285 1.2584 -1.11 8.7317
NCI-H2087 GDSC2 -0.5221 2.6622 -1.7879 12.9138
DMS 273 GDSC2 -0.518 4.8611 -2.8746 19.2521
IST-SL2 GDSC2 -0.5132 1.7574 -0.5626 29.051
NCI-H526 GDSC2 -0.4648 0.7385 -0.8035 6.6223
NCI-H1648 GDSC2 -0.4451 2.0707 -1.4262 10.41
NCI-H841 GDSC2 -0.4321 8.0929 -4.4119 26.0149
PaCa-3 GDSC2 -0.4108 1.4799 -1.105 8.2899
HCC827 GDSC2 -0.4088 2.8076 -1.7575 12.3543
NCI-H2347 GDSC2 -0.4031 2.5267 -1.6132 11.4394
HCC366 GDSC2 -0.351 4.2151 -0.9616 39.1602
NCI-H2369 GDSC2 -0.2944 5.3314 -2.9148 18.7477
NCI-H1869 GDSC2 -0.2683 1.0429 -0.759 5.6472
SK-MES-1 GDSC2 -0.2592 3.8987 -2.1693 14.3954
NCI-H1693 GDSC2 -0.2178 2.7887 -1.5797 10.6426
NCI-H2869 GDSC2 -0.2097 1.8063 -0.248 35.6258
Calu-6 GDSC2 -0.2089 4.4468 -2.3998 15.6009
LCLC-103H GDSC2 -0.2089 3.6636 -2.0087 13.2688
NCI-H1341 GDSC2 -0.2054 2.829 -1.5891 10.6632
SW1271 GDSC2 -0.1565 2.8986 -1.5817 10.4667
COR-L321 GDSC2 -0.111 3.0786 -0.3609 35.5967
NCI-H835 GDSC2 -0.1095 13.5884 -6.8857 32.2082
HCC33 GDSC2 -0.088 3.7197 -0.5152 36.1032
NCI-H2029 GDSC2 -0.0375 3.6624 -0.4426 35.5359
NCI-H2591 GDSC2 -0.0146 5.5153 -2.7698 17.0996
NCI-H2342 GDSC2 0.0368 3.9305 -1.9347 12.08
NCI-H146 GDSC2 0.0509 7.2875 -1.7748 39.1704
CAL-12T GDSC2 0.072 6.5364 -1.4238 38.1941
NCI-H2405 GDSC2 0.1129 2.0533 -0.9342 5.5946
NCI-H2595 GDSC2 0.1255 4.0107 -1.9017 11.6218
NCI-H1793 GDSC2 0.1271 6.2183 -3.0039 17.9322
NCI-H520 GDSC2 0.1569 3.3302 -1.5362 9.2664
NCI-H250 GDSC2 0.2045 7.8104 -1.8545 38.6285
NCI-H720 GDSC2 0.2242 5.0144 -2.3229 13.8647
NCI-H2030 GDSC2 0.2749 3.7295 -0.123 32.507
NCI-H1963 GDSC2 0.2919 4.6953 -2.1091 12.4088
NCI-H2170 GDSC2 0.2976 3.8697 -1.6928 9.854
NCI-H2141 GDSC2 0.3182 4.5196 -2.0004 11.682
SK-LU-1 GDSC2 0.3461 4.674 -2.0552 11.9355
NCI-H2085 GDSC2 0.3592 4.5016 -1.9589 11.3177
Lu-165 GDSC2 0.3638 4.4099 -1.9096 11.0057
NCI-H1755 GDSC2 0.4249 5.5139 -2.4114 13.816
NCI-H1355 GDSC2 0.4594 2.5478 -0.9143 4.5821
VMRC-LCD GDSC2 0.4737 3.7315 -1.4871 8.1122
HCC15 GDSC2 0.5028 3.605 -1.4026 7.5129
NCI-H64 GDSC2 0.5096 3.9545 -1.5702 8.5355
NCI-H2804 GDSC2 0.5207 4.8727 -0.2641 31.9093
Calu-3 GDSC2 0.5451 6.0129 -2.5651 14.3607
EKVX GDSC2 0.5923 3.5997 0.2627 29.0759
NCI-H1944 GDSC2 0.6323 7.2076 -3.0913 16.9522
NCI-H1092 GDSC2 0.6765 3.6821 -1.3122 6.5302
NCI-H522 GDSC2 0.713 5.1496 -2.0074 10.6795
NCI-H596 GDSC2 0.7197 2.4843 -0.7058 2.7584
NCI-H441 GDSC2 0.7885 5.3939 -2.0713 10.8688
NCI-H3255 GDSC2 0.7917 8.0546 -1.3821 34.7337
IA-LM GDSC2 0.793 6.6308 -2.68 14.3372
NCI-H1915 GDSC2 0.8928 7.7919 -3.1792 16.7014
NCI-H1838 GDSC2 0.9032 4.2836 -1.4438 6.8122
NCI-H727 GDSC2 0.9241 3.2835 -0.9503 3.8003
NCI-H196 GDSC2 0.933 2.68 -0.6654 2.1502
NCI-H2122 GDSC2 1.0295 6.0839 -2.2325 11.2157
NCI-H510A GDSC2 1.0689 6.1792 -0.2447 29.287
NCI-H1770 GDSC2 1.1257 3.8713 0.7554 24.0093
NCI-H1435 GDSC2 1.2851 4.46 -1.2716 4.9857
BEN GDSC2 1.2959 5.7633 0.1716 26.3358
NCI-H1436 GDSC2 1.3955 4.6871 0.7363 22.9304
NCI-H2803 GDSC2 1.4207 4.3743 0.8881 21.9806
COR-L88 GDSC2 1.5728 4.2472 -1.0003 2.9633
NCI-H2066 GDSC2 2.1019 3.8682 -0.5861 0.5698
NCI-H2291 GDSC2 2.2053 8.659 -0.326 25.1476
NCI-H1573 GDSC2 2.4066 4.0407 -0.53 0.2879
NCI-H2172 GDSC2 2.5447 4.4064 2.0471 10.6576
NCI-H2196 GDSC2 2.8161 9.4468 -0.1716 22.3452
NCI-H1836 GDSC2 2.8302 6.4237 1.3443 13.9784
NCI-H740 GDSC2 3.2564 13.4719 -1.8077 27.4265
NCI-H345 GDSC2 3.4704 7.7738 1.2185 12.7801
NCI-H2135 GDSC2 3.9203 10.5893 0.1741 17.3338
NCI-H2444 GDSC2 4.6714 6.355 2.7277 1.2192
⏷ Show the Full List of 182 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 -3.6468 -0.4748 -3.861 37.5298
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-150 GDSC2 -2.5763 3.5759 -4.2174 33.338
KYSE-140 GDSC2 -2.2245 1.4071 -2.9172 26.0074
TE-1 GDSC2 -1.9555 0.4762 -2.2809 21.368
EC-GI-10 GDSC2 -1.7649 3.3229 -3.2914 25.9467
KYSE-180 GDSC2 -1.5841 1.6756 -2.3604 20.2431
KYSE-270 GDSC2 -1.5062 0.5894 -1.8354 16.907
OE33 GDSC2 -1.3581 0.8574 -1.7804 15.9661
KYSE-510 GDSC2 -0.9965 2.9141 -1.2861 44.1153
TE-5 GDSC2 -0.9841 2.0788 -1.9415 15.4659
TE-4 GDSC2 -0.971 2.0179 -1.8999 15.1676
OE19 GDSC2 -0.8786 10.0569 -5.7782 31.7613
TE-8 GDSC2 -0.8509 3.0106 -2.2623 16.9074
TE-11 GDSC2 -0.805 2.0658 -0.9115 41.81
TE-6 GDSC2 -0.6027 3.3211 -2.1862 15.6054
KYSE-450 GDSC2 -0.5414 3.0551 -1.9992 14.2735
TE-10 GDSC2 -0.4739 2.4279 -0.6152 38.6959
TE-9 GDSC2 -0.3123 3.4704 -2.0018 13.5491
T.T GDSC2 -0.114 1.2711 -0.7329 4.9828
OE21 GDSC2 0.0239 5.3679 -2.664 16.3995
COLO 680N GDSC2 0.5363 3.8299 -1.4885 7.9616
KYSE-410 GDSC2 0.5506 3.6186 -1.3735 7.2133
KYSE-520 GDSC2 0.589 4.2381 -1.6505 8.8286
KYSE-70 GDSC2 1.7448 8.9164 -3.101 14.2115
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A2780 GDSC2 -5.2949 -1.0294 -5.5335 52.6861
TOV-112D GDSC2 -3.8632 -1.4462 -3.927 39.0491
OVK18 GDSC2 -3.4363 0.5702 -3.5237 65.3548
DOV13 GDSC2 -3.4056 0.1325 -3.7536 35.7431
IGROV-1 GDSC2 -3.1976 2.3652 -4.3325 36.7193
OC 314 GDSC2 -2.5577 -0.2335 -2.7312 26.5633
OVCAR-8 GDSC2 -2.4119 0.7309 -2.8626 26.5697
TYK-nu GDSC2 -2.1341 2.5467 -3.3073 27.568
ES-2 GDSC2 -1.9927 1.3214 -2.6377 23.5004
TOV-21G GDSC2 -1.7475 0.1019 -1.9359 18.5341
OAW28 GDSC2 -1.3958 2.0519 -2.3369 19.3601
OVISE GDSC2 -1.3952 0.7098 -1.7618 16.0141
Caov-3 GDSC2 -1.3824 3.7525 -1.9358 47.8017
Caov-4 GDSC2 -1.2014 0.678 -1.5431 13.9404
JHOS-4 GDSC2 -1.1507 3.045 -1.4864 45.5914
JHOS-2 GDSC2 -1.1493 1.9229 -1.2591 45.1576
OVTOKO GDSC2 -1.1363 2.6341 -2.3525 18.4646
RMG-I GDSC2 -0.7803 0.5104 -1.03 9.2154
Kuramochi GDSC2 -0.6927 2.31 -1.7731 13.4017
SK-OV-3 GDSC2 -0.4762 3.0012 -1.9138 13.537
OV-90 GDSC2 -0.3454 4.6078 -2.5977 17.165
OVCAR-3 GDSC2 -0.3338 3.7632 -2.1666 14.6135
OVCAR-5 GDSC2 -0.234 2.7157 -1.5575 10.5535
OV56 GDSC2 -0.0216 2.3373 -1.1867 7.5757
FU-OV-1 GDSC2 0.0306 2.816 -1.3826 8.6603
EFO-21 GDSC2 0.6911 8.8069 -3.8416 20.3718
OVKATE GDSC2 0.6913 3.0559 -0.9973 4.5643
OAW42 GDSC2 0.7838 4.6638 -1.7153 8.743
OVCAR-4 GDSC2 1.4545 9.3793 -3.5395 17.0256
EFO-27 GDSC2 3.1104 11.1372 -0.7633 24.032
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PSN1 GDSC2 -3.0764 0.0477 -3.3705 32.312
KP-4 GDSC2 -2.5976 -0.0062 -2.8332 27.2856
CFPAC-1 GDSC2 -2.5314 0.6958 -2.9797 27.7301
MIA PaCa-2 GDSC2 -2.077 1.2011 -2.679 24.0904
DAN-G GDSC2 -1.9853 0.6742 -2.382 22.0587
PL4 GDSC2 -1.8955 4.1356 -3.8017 28.795
PaTu 8988t GDSC2 -1.6686 1.1536 -2.2279 19.8337
KP-1N GDSC2 -1.5769 2.0904 -2.537 21.2151
HuP-T3 GDSC2 -1.0957 1.6492 -1.852 15.3455
SUIT-2 GDSC2 -1.0758 2.7973 -2.3721 18.3564
Panc 03.27 GDSC2 -0.8291 3.2426 -2.3552 17.377
Capan-1 GDSC2 -0.5239 3.4917 -2.1996 15.4244
BxPC-3 GDSC2 -0.509 4.1349 -2.5056 17.1682
YAPC GDSC2 -0.4228 2.4567 -1.5963 11.3983
Panc 02.03 GDSC2 -0.3362 2.5642 -1.572 10.9668
PaTu 8902 GDSC2 0.0787 5.7157 -2.7926 16.945
Panc 10.05 GDSC2 0.2886 3.4145 -1.4731 8.5104
KP-2 GDSC2 0.3181 2.8587 -1.1737 6.5545
HPAC GDSC2 0.39 7.1658 -3.2633 18.4964
SU.86.86 GDSC2 0.5121 4.532 -1.8546 10.2756
HPAF-II GDSC2 0.655 3.7094 -1.3412 6.7596
AsPC-1 GDSC2 0.7156 6.7251 -2.7863 15.1205
Panc 04.03 GDSC2 0.7331 4.4249 -1.6352 8.3782
KP-3 GDSC2 0.8045 5.3984 -2.0616 10.7711
SW1990 GDSC2 0.8826 10.1774 -4.3732 22.0791
QGP-1 GDSC2 0.9863 8.5789 -1.4388 34.0821
HuP-T4 GDSC2 1.0545 8.517 -3.4148 17.439
Hs 766T GDSC2 1.0792 7.2713 -2.7801 14.1467
MZ-PC-1 GDSC2 1.3043 4.861 0.5689 24.2332
Capan-2 GDSC2 1.378 4.4786 -1.2216 4.5216
Panc 08.13 GDSC2 1.9654 3.7935 -0.615 0.7517
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2052 GDSC2 -1.6378 2.1743 -2.6364 22.0145
IST-Mes1 GDSC2 -1.1978 6.4957 -4.2931 28.1154
MSTO-211H GDSC2 -1.1252 0.5752 -1.4219 12.9217
MPP 89 GDSC2 -1.1033 5.0364 -3.4879 24.3631
NCI-H2452 GDSC2 -0.4071 6.7975 -3.7437 23.1769
NCI-H28 GDSC2 0.2135 7.7193 -3.6832 21.0076
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2 -4.1926 -0.1001 -4.5486 43.1201
22Rv1 GDSC2 -2.263 1.4157 -2.9614 26.4086
VCaP GDSC2 -0.9928 2.3909 -2.0981 16.4376
DU145 GDSC2 -0.4641 2.2519 -1.5328 11.1384
PC-3 GDSC2 0.0427 2.678 -1.3036 8.1272
NCI-H660 GDSC2 3.943 6.9539 1.994 6.7594
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 -0.1215 3.4276 -1.816 11.8196
Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
WM793 GDSC2 -4.742 -0.1603 -5.1322 47.9926
LOX-IMVI GDSC2 -3.8683 -0.0303 -4.2133 40.109
RPMI-7951 GDSC2 -3.5441 -0.2429 -3.8043 36.719
A2058 GDSC2 -3.4163 -0.7378 -3.5558 34.9462
A-375 GDSC2 -3.1511 0.3902 -3.2081 48.758
DJM-1 GDSC2 -3.1433 1.556 -3.3419 62.0812
A101D GDSC2 -3.0642 0.0892 -3.3688 32.2419
MZ-MEL-2 GDSC2 -3.0363 1.2055 -3.1745 61.7301
COLO 679 GDSC2 -2.7576 -0.8325 -2.8298 28.04
SK-MEL-30 GDSC2 -2.6601 2.0712 -2.9124 58.1765
M14 GDSC2 -2.6108 0.5321 -3.0105 28.261
G-mel GDSC2 -2.297 0.2793 -2.3163 56.1978
CHL-1 GDSC2 -2.2652 -0.0596 -2.456 23.7296
WM35 GDSC2 -2.1651 0.5817 -2.5439 23.7462
IPC-298 GDSC2 -2.1581 1.4578 -2.2719 54.5251
IGR-1 GDSC2 -2.1498 -0.1603 -2.3044 22.3809
WM278 GDSC2 -1.9891 1.4816 -2.6993 23.8202
G-361 GDSC2 -1.875 0.3251 -2.1434 20.2493
HT-144 GDSC2 -1.8488 0.8706 -2.3078 21.0509
A-388 GDSC2 -1.841 3.6275 -2.3988 51.3792
SK-MEL-24 GDSC2 -1.7801 0.6933 -2.168 19.9689
COLO 800 GDSC2 -1.6559 2.5462 -1.9201 49.9596
HMV-II GDSC2 -1.6329 1.6788 -2.4121 20.7356
COLO 829 GDSC2 -1.61 3.3544 -3.1543 24.6494
IST-MEL1 GDSC2 -1.5333 1.6416 -2.2933 19.6539
SH-4 GDSC2 -1.5225 2.1711 -2.5186 20.8953
UACC-62 GDSC2 -1.5081 1.5153 -2.2124 19.0854
MZ-MEL-7 GDSC2 -1.3885 1.6264 -1.4744 47.4116
A-431 GDSC2 -1.3653 2.7013 -1.6382 47.414
Hs 938.T GDSC2 -1.3207 2.2906 -1.505 46.9052
GAK GDSC2 -1.2715 1.4801 -1.954 16.6325
UACC-257 GDSC2 -1.2254 0.3596 -1.4503 13.5133
Mel JuSo GDSC2 -1.2192 2.9516 -2.5839 20.098
COLO 783 GDSC2 -1.1751 1.0919 -1.2012 45.2087
COLO 792 GDSC2 -1.1659 0.173 -1.3236 12.5421
WM1552C GDSC2 -1.1638 2.0279 -2.0943 17.049
WM115 GDSC2 -1.1202 1.1462 -1.6523 14.2501
SK-MEL-5 GDSC2 -1.0451 1.9245 -1.1478 44.1349
SK-MEL-2 GDSC2 -0.985 -0.0182 -1.0701 10.3323
WT2-iPS GDSC2 -0.981 1.5522 -1.035 32.5866
CP50-MEL-B GDSC2 -0.9438 1.1239 -0.9638 42.886
SK-MEL-28 GDSC2 -0.8414 2.7488 -1.079 42.5507
LB373-MEL-D GDSC2 -0.8216 2.2158 -0.9531 42.0521
SK-MEL-3 GDSC2 -0.5867 1.0066 -0.5933 39.255
Hs 940.T GDSC2 -0.581 5.4293 -1.6537 42.2323
LB2518-MEL GDSC2 -0.4999 2.5092 -0.6585 39.0174
MMAc-SF GDSC2 -0.4975 0.6749 -0.4983 38.3321
SK-MEL-31 GDSC2 -0.2085 3.5716 -0.602 37.1099
IGR-37 GDSC2 -0.0788 2.6449 -1.3886 9.0195
MeWo GDSC2 -0.0664 3.8313 -1.9713 12.6085
Mel Ho GDSC2 0.0933 3.7871 -0.3388 34.4025
VMRC-MELG GDSC2 0.1875 1.8322 0.1651 31.5665
SK-MEL-1 GDSC2 0.2357 1.6514 -0.6384 3.4066
CP66-MEL GDSC2 0.3092 3.079 0.0971 31.2913
RVH-421 GDSC2 0.4528 1.7057 0.4454 28.8289
451Lu GDSC2 0.4632 2.999 0.284 29.5969
EquiPSC Line K2 GDSC2 -1.2196 1.6198 -1.2943 45.7611
⏷ Show the Full List of 57 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 -6.1762 -2.2379 -6.194 85.1272
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EW-8 GDSC2 -6.6106 -4.8708 -6.611 66.2263
G-401 GDSC2 -5.4084 -1.1299 -5.6367 53.6558
KYM-1 GDSC2 -4.3178 -1.549 -4.3972 43.5921
G-402 GDSC2 -3.9912 0.2017 -4.4124 41.4627
SW982 GDSC2 -3.9297 1.0233 -4.6061 41.5783
STS-0421 GDSC2 -3.5343 1.7176 -3.7915 64.3503
VA-ES-BJ GDSC2 -3.3433 0.252 -3.7204 35.2668
MES-SA GDSC2 -3.1195 0.1733 -3.4533 32.9169
TE 441.T GDSC2 -3.1044 0.7048 -3.1875 62.7865
A-204 GDSC2 -3.0044 0.1322 -3.3158 31.6879
Rh41 GDSC2 -2.8222 -0.7066 -2.9198 28.8171
HT-1080 GDSC2 -1.8831 0.2187 -2.1187 20.1498
Hs 633.T GDSC2 -1.742 0.89 -2.2012 19.9919
Rh30 GDSC2 -1.7302 0.6246 -2.0893 19.31
SK-UT-1 GDSC2 -1.6572 0.6384 -2.0157 18.579
SW872 GDSC2 -1.5757 1.1707 -2.1371 18.9273
MFH-ino GDSC2 -1.3726 1.49 -2.062 17.6678
RD GDSC2 -1.2564 2.4427 -2.3792 19.0684
GCT GDSC2 -1.1278 3.751 -2.882 21.4017
SK-LMS-1 GDSC2 -0.8691 1.8761 -1.7335 13.786
SW684 GDSC2 0.6157 4.8021 -1.9092 10.3382
RKN GDSC2 0.7111 3.0994 -1.0046 4.5658
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AGS GDSC2 -4.1223 -0.881 -4.2925 41.9672
SNU-16 GDSC2 -3.8965 -0.2957 -4.1754 40.1599
HSC-39 GDSC2 -3.8674 -0.6994 -4.0523 39.5579
NUGC-3 GDSC2 -3.7544 1.2669 -4.5018 40.2649
SNU-1 GDSC2 -3.6119 0.1493 -3.9836 37.7971
ECC10 GDSC2 -3.2179 -1.0891 -3.2855 32.628
HGC-27 GDSC2 -3.016 0.3037 -3.3791 32.0452
SK-GT-2 GDSC2 -2.9801 0.2817 -3.3333 31.6487
23132/87 GDSC2 -2.8859 0.773 -3.3899 31.4434
RF-48 GDSC2 -2.7743 1.7431 -3.6335 31.9831
MKN1 GDSC2 -2.4737 2.3404 -3.5664 30.275
RERF-GC-1B GDSC2 -2.1942 -0.2026 -2.3425 22.7919
MKN45 GDSC2 -2.1181 1.2516 -2.7426 24.6134
IM95 GDSC2 -2.0423 -0.1656 -2.1858 21.2442
SNU-5 GDSC2 -1.7801 0.0462 -1.9555 18.7894
SCH GDSC2 -1.3526 1.0266 -1.3812 46.972
TMK-1 GDSC2 -1.3309 1.8551 -1.4435 46.8992
Fu97 GDSC2 -1.3096 4.4156 -3.3758 24.5857
Hs 746.T GDSC2 -1.1082 2.1263 -2.0853 16.7869
NCI-N87 GDSC2 -1.053 2.2811 -2.1042 16.694
MKN28 GDSC2 -0.8453 2.6987 -2.1054 15.9533
ECC12 GDSC2 -0.2635 4.1958 -0.8602 38.3331
NUGC-4 GDSC2 -0.2023 2.1772 -1.2614 8.5936
OCUM-1 GDSC2 -0.1987 3.0569 -1.6971 11.3167
GCIY GDSC2 0.3387 4.9941 -2.2207 12.9422
TGBC11TKB GDSC2 0.6618 3.2398 -1.1069 5.301
MKN7 GDSC2 0.8963 6.2025 -0.4309 23.7267
KATO III GDSC2 1.0567 6.2555 -2.2967 11.5188
SNG-M GDSC2 -1.9162 0.9588 -2.4135 21.9325
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-62 GDSC2 -3.8686 -0.106 -4.1934 40.0466
FTC-133 GDSC2 -3.0814 0.0167 -3.3674 32.3232
IHH-4 GDSC2 -3.0336 -0.2543 -3.2448 31.4932
8505C GDSC2 -2.7233 1.5696 -3.5105 31.1979
K5 GDSC2 -2.6816 0.1726 -2.9754 28.4193
B-CPAP GDSC2 -2.0216 1.4784 -2.7322 24.1381
TT2609-C02 GDSC2 -1.9009 2.6442 -3.1143 25.6279
BHT-101 GDSC2 -1.8238 1.0311 -2.3432 21.1419
ASH-3 GDSC2 -1.4906 0.3704 -1.7411 16.3078
KMH-2 GDSC2 -1.3917 1.2782 -1.4409 47.3902
8305C GDSC2 -0.977 2.4337 -2.1032 16.4109
HTC-C3 GDSC2 -0.8682 0.9543 -1.3094 11.2173
TT GDSC2 -0.3315 4.0602 -2.3126 15.4738
CGTH-W-1 GDSC2 -0.0894 3.3159 -1.733 11.2089
ML-1 [Human leukemia] GDSC2 0.4479 4.4572 -0.1842 31.9144
WRO GDSC2 0.4905 2.9917 -1.1093 5.7185
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-3 GDSC2 -4.5095 -0.3015 -4.8424 45.9141
JHU-011 GDSC2 -4.2906 -1.2813 -4.3011 74.1766
SAS GDSC2 -4.2305 -0.6143 -4.4648 43.1722
BB30-HNC GDSC2 -3.789 -0.9052 -3.8006 69.9992
PCI-15A GDSC2 -3.3532 -1.3847 -3.3543 66.7652
NCI-H3118 GDSC2 -2.9873 0.4803 -3.4029 32.0106
HO-1-N-1 GDSC2 -2.9442 0.4516 -3.3469 31.5329
FaDu GDSC2 -2.8338 -0.6371 -2.9449 29.0022
BICR 22 GDSC2 -2.719 1.0775 -3.3183 30.2919
PCI-04B GDSC2 -2.6227 0.2437 -2.6498 59.2043
JHU-029 GDSC2 -2.3322 0.8516 -2.3896 56.3068
HSC-2 GDSC2 -2.1455 0.7715 -2.5896 23.9075
OSC-19 GDSC2 -2.0894 3.2676 -2.5689 53.3127
KOSC-2 GDSC2 -2.0782 1.3161 -2.1692 53.8668
JHU-022 GDSC2 -1.9895 3.0173 -3.3731 27.2649
CAL-33 GDSC2 -1.9175 1.3297 -2.5617 22.7603
CAL-27 GDSC2 -1.9099 1.3625 -2.5672 22.7584
HSC-4 GDSC2 -1.8281 1.1605 -2.3991 21.4741
SKN-3 GDSC2 -1.8089 0.4888 -2.1263 19.8615
KON GDSC2 -1.6137 2.0048 -1.7705 49.573
Ca9-22 GDSC2 -1.556 1.1186 -2.095 18.6041
BB49-HNC GDSC2 -1.3709 5.8225 -4.12 28.068
PE/CA-PJ15 GDSC2 -1.2649 1.5617 -1.3357 46.1937
BICR 78 GDSC2 -1.2174 2.2162 -2.2349 18.081
HO-1-u-1 GDSC2 -1.0672 0.5395 -1.3463 12.2426
DOK GDSC2 -1.0661 9.3658 -5.5986 31.8716
BICR 10 GDSC2 -1.0046 3.7919 -2.7868 20.4413
Detroit 562 GDSC2 -0.9745 3.0085 -2.3775 18.021
PCI-06A GDSC2 -0.8793 2.5187 -1.0713 42.7839
SCC-15 GDSC2 -0.4218 1.7703 -1.2573 9.2778
PCI-30 GDSC2 -0.4068 4.4375 -2.5662 17.1828
SAT [Human HNSCC] GDSC2 -0.3291 5.1438 -2.851 18.5143
OSC-20 GDSC2 -0.2772 4.6156 -2.5427 16.6372
UPCI-SCC-090 GDSC2 -0.0684 2.9394 -1.5271 9.8592
BICR 31 GDSC2 0.188 4.6527 -0.5356 34.7066
SCC-9 GDSC2 0.1961 5.5591 -2.6179 15.6355
SCC-4 GDSC2 0.3011 2.1314 -0.8263 4.4192
BHY GDSC2 0.5857 3.6489 0.2405 29.2191
SCC-25 GDSC2 1.9708 3.5736 1.7717 14.6256
LB771-HNC GDSC2 2.5276 4.8856 -0.7936 0.9761
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KU-19-19 GDSC2 -3.8335 -0.0323 -4.1748 39.7722
639V GDSC2 -3.4152 -1.6095 -3.4406 34.3974
BFTC-905 GDSC2 -2.9871 0.6396 -3.4545 32.2468
647V GDSC2 -2.7767 -0.2187 -2.9735 28.8695
HT-1197 GDSC2 -2.149 0.6229 -2.5407 23.6571
5637 GDSC2 -1.8558 1.8545 -2.7181 23.3575
UM-UC-3 GDSC2 -1.6736 0.2746 -1.9082 18.0488
SW780 GDSC2 -1.6304 1.885 -2.4998 21.2218
CAL-29 GDSC2 -1.5656 1.6964 -2.3505 20.1118
RT-4 GDSC2 -1.2238 2.9141 -2.5703 20.0387
RT-112 GDSC2 -0.7356 2.9024 -2.102 15.5512
SW1710 GDSC2 -0.7056 2.0145 -1.6423 12.6423
TCCSUP GDSC2 -0.623 1.5857 -1.3573 10.5938
T24 GDSC2 0.8458 3.1263 0.6704 25.7577
J82 GDSC2 1.6395 4.4892 -1.0704 3.2367
HT-1376 GDSC2 2.735 12.8332 -4.3049 17.4361
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NT2-D1 GDSC2 -4.0957 -0.0033 -4.4688 42.2832
C-33 A GDSC2 -4.0373 -0.8218 -4.2119 41.1637
SiSo GDSC2 -4.0174 -1.6303 -4.07 40.5367
NEC8 GDSC2 -3.9928 -1.9406 -4.0184 40.1816
JEG-3 GDSC2 -3.9586 3.8088 -4.7617 63.7009
JAR GDSC2 -3.9038 0.7336 -4.037 68.0759
HEY GDSC2 -3.5336 0.0033 -3.8572 36.8709
KGN GDSC2 -3.2464 0.8141 -3.7944 35.048
BPH-1 GDSC2 -3.2442 -0.1091 -3.5113 33.8306
SW954 GDSC2 -2.9783 1.3262 -3.1295 61.1802
TC-YIK GDSC2 -2.6702 0.3342 -3.0117 28.5498
DSH1 GDSC2 -2.5966 1.2161 -3.2388 29.3286
PWR-1E GDSC2 -2.2408 1.3202 -2.8998 25.9893
ME-180 GDSC2 -2.1122 1.0574 -2.6606 24.1454
C-4-I GDSC2 -1.9441 0.2479 -2.1942 20.8397
Ca Ski GDSC2 -1.9088 1.2369 -2.515 22.4644
PA-1 GDSC2 -1.7903 1.3942 -2.4547 21.6268
CAL-39 GDSC2 -1.7277 2.2004 -2.7392 22.9437
OVCA433 GDSC2 -1.7268 1.9106 -1.8766 50.6019
MS751 GDSC2 -1.6617 2.158 -2.6533 22.2042
ACC-OV7 GDSC2 -1.5693 2.8387 -1.8922 49.2247
OVMIU GDSC2 -0.9764 1.7817 -1.7944 14.5502
SKN GDSC2 -0.9173 5.4018 -3.4989 23.757
OMC-1 [Human cervical carcinoma] GDSC2 -0.7474 2.8589 -1.0017 41.7138
LB831-BLC GDSC2 -0.5597 2.3623 -1.6748 12.3403
NCC-IT GDSC2 -0.4932 0.3935 -0.6801 5.9948
DoTc2 4510 GDSC2 -0.4663 1.7103 -1.2692 9.5022
PEO1 GDSC2 -0.358 2.7652 -1.6912 11.7794
HT-3 GDSC2 -0.2127 5.0264 -2.6926 17.2796
HeLa GDSC2 -0.1267 3.4354 -1.8244 11.8874
SKG-IIIa GDSC2 -0.1082 2.9424 -1.5623 10.1995
SiHa GDSC2 -0.1022 1.7663 -0.9697 6.4433
SW756 GDSC2 -0.0476 5.3491 -2.7143 16.8934
SW962 GDSC2 0.284 3.3273 0.0051 31.8623
HEC-1 GDSC2 0.2871 3.3089 -1.4217 8.1929
UWB1.289 GDSC2 0.2924 3.8502 -0.1423 32.5056
OVCA420 GDSC2 0.8131 5.5179 -2.1141 11.0596
JHOS-3 GDSC2 0.9869 4.2694 0.4641 26.1932
OV17R GDSC2 2.6983 6.1738 1.3479 14.3949
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Epirubicin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [17]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [17]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Epirubicin and LEE011. Solid tumour/cancer [2A00-2F9Z] [18]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Epirubicin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [18]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [19]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [18]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [17]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Epirubicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [17]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tretinoin. Acne vulgaris [ED80] [17]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Isotretinoin. Acne vulgaris [ED80] [17]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [17]
Pioglitazone DMKJ485 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Pioglitazone. Acute diabete complication [5A2Y] [17]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Epirubicin and Ivosidenib. Acute myeloid leukaemia [2A60] [20]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tagraxofusp. Acute myeloid leukaemia [2A60] [17]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Midostaurin. Acute myeloid leukaemia [2A60] [18]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Idarubicin. Acute myeloid leukaemia [2A60] [18]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Daunorubicin. Acute myeloid leukaemia [2A60] [18]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Arn-509. Acute myeloid leukaemia [2A60] [19]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Gilteritinib. Acute myeloid leukaemia [2A60] [21]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Oliceridine. Acute pain [MG31] [18]
Oxandrolone DMU9MYJ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Oxandrolone. Alcoholic liver disease [DB94] [17]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Galantamine. Alzheimer disease [8A20] [18]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Rivastigmine. Alzheimer disease [8A20] [18]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Donepezil. Alzheimer disease [8A20] [18]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Epirubicin and Metronidazole. Amoebiasis [1A36] [17]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Epirubicin and Ivabradine. Angina pectoris [BA40] [19]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Epirubicin and Bepridil. Angina pectoris [BA40] [18]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Epirubicin and Dronedarone. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Epirubicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [22]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [18]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Oxymetholone. Aplastic anaemia [3A70] [17]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Cilostazol. Arterial occlusive disease [BD40] [18]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Voriconazole. Aspergillosis [1F20] [18]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Posaconazole. Aspergillosis [1F20] [18]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Levalbuterol. Asthma [CA23] [23]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Terbutaline. Asthma [CA23] [24]
Zafirlukast DMHNQOG Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Zafirlukast. Asthma [CA23] [17]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pirbuterol. Asthma [CA23] [24]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Salbutamol. Asthma [CA23] [23]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Epirubicin and Roflumilast. Asthma [CA23] [19]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Formoterol. Asthma [CA23] [24]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [19]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Desipramine. Attention deficit hyperactivity disorder [6A05] [18]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ofloxacin. Bacterial infection [1A00-1C4Z] [25]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Clavulanate. Bacterial infection [1A00-1C4Z] [17]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [18]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Clarithromycin. Bacterial infection [1A00-1C4Z] [18]
Trovafloxacin DM6AN32 Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [26]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Epirubicin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [18]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Epirubicin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [25]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [25]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Norfloxacin. Bacterial infection [1A00-1C4Z] [25]
ABT-492 DMJFD2I Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [26]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Levofloxacin. Bacterial infection [1A00-1C4Z] [25]
Minocycline DMVN5OH Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Minocycline. Bacterial infection [1A00-1C4Z] [17]
Lomefloxacin DMVRH9C Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [26]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Retigabine. Behcet disease [4A62] [18]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Epirubicin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [27]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Loperamide. Bowel habit change [ME05] [28]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Eribulin. Breast cancer [2C60-2C6Y] [18]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lapatinib. Breast cancer [2C60-2C6Y] [18]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and LY2835219. Breast cancer [2C60-2C6Y] [17]
Tucatinib DMBESUA Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [29]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tamoxifen. Breast cancer [2C60-2C6Y] [18]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Epirubicin and Toremifene. Breast cancer [2C60-2C6Y] [18]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Epirubicin and Sotalol. Cardiac arrhythmia [BC9Z] [18]
Atorvastatin DMF28YC Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [17]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Chenodiol. Cholelithiasis [DC11] [17]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [30]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [24]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [23]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [24]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [24]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [24]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Isoproterenol. Conduction disorder [BC63] [23]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Halothane. Corneal disease [9A76-9A78] [18]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Propofol. Corneal disease [9A76-9A78] [31]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Sevoflurane. Corneal disease [9A76-9A78] [18]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Probucol. Coronary atherosclerosis [BA80] [18]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Clofazimine. Crohn disease [DD70] [32]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Epirubicin and Pasireotide. Cushing syndrome [5A70] [18]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Osilodrostat. Cushing syndrome [5A70] [19]
Ivacaftor DMZC1HS Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ivacaftor. Cystic fibrosis [CA25] [17]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Sertraline. Depression [6A70-6A7Z] [18]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Trimipramine. Depression [6A70-6A7Z] [18]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Imipramine. Depression [6A70-6A7Z] [18]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Fluoxetine. Depression [6A70-6A7Z] [18]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Nortriptyline. Depression [6A70-6A7Z] [18]
Nefazodone DM4ZS8M Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Nefazodone. Depression [6A70-6A7Z] [17]
Duloxetine DM9BI7M Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Duloxetine. Depression [6A70-6A7Z] [17]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Epirubicin and Escitalopram. Depression [6A70-6A7Z] [18]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Clomipramine. Depression [6A70-6A7Z] [18]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Trazodone. Depression [6A70-6A7Z] [33]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Amoxapine. Depression [6A70-6A7Z] [18]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Doxepin. Depression [6A70-6A7Z] [18]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Maprotiline. Depression [6A70-6A7Z] [18]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [17]
PMID28454500-Compound-96 DM2A75P Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and PMID28454500-Compound-96. Discovery agent [N.A.] [17]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [18]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Deutetrabenazine. Dystonic disorder [8A02] [34]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ingrezza. Dystonic disorder [8A02] [35]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Felbamate. Epilepsy/seizure [8A61-8A6Z] [17]
Fosphenytoin DMOX3LB Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [17]
Carbamazepine DMZOLBI Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Cannabidiol. Epileptic encephalopathy [8A62] [17]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Dantrolene. Fever [MG26] [17]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Solifenacin. Functional bladder disorder [GC50] [18]
Itraconazole DMCR1MV Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Itraconazole. Fungal infection [1F29-1F2F] [17]
Caspofungin DMGQIPT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Caspofungin. Fungal infection [1F29-1F2F] [17]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pentamidine. Fungal infection [1F29-1F2F] [18]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Terbinafine. Fungal infection [1F29-1F2F] [17]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ketoconazole. Fungal infection [1F29-1F2F] [17]
Atovaquone DMY4UMW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Atovaquone. Fungal infection [1F29-1F2F] [17]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Epirubicin and Cisapride. Gastro-oesophageal reflux disease [DA22] [18]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [18]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lamivudine. Hepatitis virus infection [1E50-1E51] [17]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [17]
Isoniazid DM5JVS3 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Rifampin DMA8J1G Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [17]
Zidovudine DM4KI7O Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [17]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [36]
Stavudine DM6DEK9 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Stavudine. Human immunodeficiency virus disease [1C60-1C62] [17]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [17]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Epirubicin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [37]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Epirubicin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [38]
Zalcitabine DMH7MUV Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [17]
Didanosine DMI2QPE Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Didanosine. Human immunodeficiency virus disease [1C60-1C62] [17]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [18]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Darunavir DMN3GCH Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Maraviroc DMTL94F Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [17]
Ritonavir DMU764S Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ritonavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Simvastatin DM30SGU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Simvastatin. Hyper-lipoproteinaemia [5C80] [17]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fluvastatin. Hyper-lipoproteinaemia [5C80] [17]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fenofibrate. Hyper-lipoproteinaemia [5C80] [17]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [17]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Epirubicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [39]
BMS-201038 DMQTAGO Moderate Decreased clearance of Epirubicin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [40]
Moexipril DM26E4B Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Moexipril. Hypertension [BA00-BA04] [17]
Captopril DM458UM Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Captopril. Hypertension [BA00-BA04] [17]
Trandolapril DM4L6EU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Trandolapril. Hypertension [BA00-BA04] [17]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Methyldopa. Hypertension [BA00-BA04] [17]
Fosinopril DM9NJ52 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fosinopril. Hypertension [BA00-BA04] [17]
Labetalol DMK8U72 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Labetalol. Hypertension [BA00-BA04] [17]
Enalapril DMNFUZR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Enalapril. Hypertension [BA00-BA04] [17]
Perindopril DMOPZDT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Perindopril. Hypertension [BA00-BA04] [17]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Quinapril. Hypertension [BA00-BA04] [17]
Lisinopril DMUOK4C Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lisinopril. Hypertension [BA00-BA04] [17]
Tolvaptan DMIWFRL Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [17]
Vitamin B3 DMQVRZH Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Vitamin B3. Inborn lipid metabolism error [5C52] [17]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [17]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [17]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [19]
Testosterone DM7HUNW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Testosterone. Low bone mass disorder [FB83] [17]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Epirubicin and Denosumab. Low bone mass disorder [FB83] [41]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Epirubicin and Crizotinib. Lung cancer [2C25] [42]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Epirubicin and Porfimer Sodium. Lung cancer [2C25] [43]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Epirubicin and Ceritinib. Lung cancer [2C25] [18]
Erlotinib DMCMBHA Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Erlotinib. Lung cancer [2C25] [17]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lurbinectedin. Lung cancer [2C25] [17]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Alectinib. Lung cancer [2C25] [17]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Epirubicin and Osimertinib. Lung cancer [2C25] [44]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and BIBW 2992. Lung cancer [2C25] [17]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Pralsetinib. Lung cancer [2C25] [17]
Capmatinib DMYCXKL Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [45]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Epirubicin and Selpercatinib. Lung cancer [2C25] [19]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Epirubicin and Lumefantrine. Malaria [1F40-1F45] [17]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Epirubicin and Halofantrine. Malaria [1F40-1F45] [46]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Epirubicin and Chloroquine. Malaria [1F40-1F45] [47]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Epirubicin and Hydroxychloroquine. Malaria [1F40-1F45] [47]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Quinine. Malaria [1F40-1F45] [18]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Primaquine. Malaria [1F40-1F45] [18]
Sulphadoxine DMZI2UF Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Sulphadoxine. Malaria [1F40-1F45] [17]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [19]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [17]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and IPI-145. Mature B-cell leukaemia [2A82] [17]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Epirubicin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [48]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Clofarabine. Mature B-cell lymphoma [2A85] [49]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Blinatumomab. Mature B-cell lymphoma [2A85] [17]
Vincristine DMINOX3 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Vincristine. Mature B-cell lymphoma [2A85] [17]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Cytarabine. Mature B-cell lymphoma [2A85] [17]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Arry-162. Melanoma [2C30] [17]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Epirubicin and Vemurafenib. Melanoma [2C30] [18]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ipilimumab. Melanoma [2C30] [17]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and LGX818. Melanoma [2C30] [50]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Danazol. Menstrual cycle bleeding disorder [GA20] [17]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Riluzole. Motor neuron disease [8B60] [17]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Epirubicin and Panobinostat. Multiple myeloma [2A83] [51]
Lenalidomide DM6Q7U4 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lenalidomide. Multiple myeloma [2A83] [17]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Epirubicin and Thalidomide. Multiple myeloma [2A83] [52]
Elotuzumab DMEYHG9 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Elotuzumab. Multiple myeloma [2A83] [17]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tecfidera. Multiple sclerosis [8A40] [17]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Epirubicin and Siponimod. Multiple sclerosis [8A40] [17]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Epirubicin and Fingolimod. Multiple sclerosis [8A40] [53]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Epirubicin and Ozanimod. Multiple sclerosis [8A40] [19]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Romidepsin. Mycosis fungoides [2B01] [18]
Fedratinib DM4ZBK6 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fedratinib. Myeloproliferative neoplasm [2A20] [17]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Epirubicin and Nilotinib. Myeloproliferative neoplasm [2A20] [18]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Dasatinib. Myeloproliferative neoplasm [2A20] [54]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Epirubicin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [55]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Epirubicin and Droperidol. Nausea/vomiting [MD90] [18]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Promethazine. Nausea/vomiting [MD90] [18]
Rolapitant DM8XP26 Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [56]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Epirubicin and Dolasetron. Nausea/vomiting [MD90] [18]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ondansetron. Nausea/vomiting [MD90] [18]
Bupropion DM5PCS7 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Bupropion. Nicotine use disorder [6C4A] [17]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Entrectinib. Non-small cell lung cancer [2C25] [17]
Orlistat DMRJSP8 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Orlistat. Obesity [5B80-5B81] [17]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Epirubicin and Levomethadyl Acetate. Opioid use disorder [6C43] [19]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lofexidine. Opioid use disorder [6C43] [18]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Rucaparib. Ovarian cancer [2C73] [18]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Dextropropoxyphene. Pain [MG30-MG3Z] [57]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Buprenorphine. Pain [MG30-MG3Z] [18]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Triclabendazole. Parasitic worm infestation [1F90] [18]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pimavanserin. Parkinsonism [8A00] [58]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Apomorphine. Parkinsonism [8A00] [18]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Famotidine. Peptic ulcer [DA61] [17]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Epirubicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [59]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Epirubicin and Lefamulin. Pneumonia [CA40] [60]
Lonafarnib DMGM2Z6 Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Lonafarnib. Premature ageing appearance [LD2B] [61]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Ritodrine. Preterm labour/delivery [JB00] [24]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Degarelix. Prostate cancer [2C82] [19]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Epirubicin and ABIRATERONE. Prostate cancer [2C82] [19]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Nilutamide. Prostate cancer [2C82] [19]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Enzalutamide. Prostate cancer [2C82] [19]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Flutamide. Prostate cancer [2C82] [19]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Relugolix. Prostate cancer [2C82] [19]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Bicalutamide. Prostate cancer [2C82] [19]
Acitretin DM8BKU9 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Acitretin. Psoriasis [EA90] [17]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Levomepromazine. Psychotic disorder [6A20-6A25] [18]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Fluphenazine. Psychotic disorder [6A20-6A25] [18]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Triflupromazine. Psychotic disorder [6A20-6A25] [18]
Ambrisentan DMD1QXW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ambrisentan. Pulmonary hypertension [BB01] [17]
Bosentan DMIOGBU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Bosentan. Pulmonary hypertension [BB01] [17]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Axitinib. Renal cell carcinoma [2C90] [17]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Epirubicin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [62]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tocilizumab. Rheumatoid arthritis [FA20] [17]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Epirubicin and Canakinumab. Rheumatoid arthritis [FA20] [63]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Epirubicin and Rilonacept. Rheumatoid arthritis [FA20] [63]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Epirubicin and Golimumab. Rheumatoid arthritis [FA20] [64]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Sarilumab. Rheumatoid arthritis [FA20] [17]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Epirubicin and Leflunomide. Rheumatoid arthritis [FA20] [39]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Quetiapine. Schizophrenia [6A20] [18]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Epirubicin and Mesoridazine. Schizophrenia [6A20] [18]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Epirubicin and Thioridazine. Schizophrenia [6A20] [18]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Aripiprazole. Schizophrenia [6A20] [17]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Epirubicin and Iloperidone. Schizophrenia [6A20] [18]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Paliperidone. Schizophrenia [6A20] [18]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Epirubicin and Haloperidol. Schizophrenia [6A20] [18]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Perphenazine. Schizophrenia [6A20] [18]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Chlorpromazine. Schizophrenia [6A20] [18]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Risperidone. Schizophrenia [6A20] [18]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Epirubicin and Amisulpride. Schizophrenia [6A20] [65]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Asenapine. Schizophrenia [6A20] [18]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Epirubicin and Pimozide. Schizophrenia [6A20] [19]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Epirubicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [66]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Vardenafil. Sexual dysfunction [HA00-HA01] [18]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pitolisant. Somnolence [MG42] [18]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [18]
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Disulfiram. Substance abuse [6C40] [17]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Naltrexone. Substance abuse [6C40] [17]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Adenosine. Supraventricular tachyarrhythmia [BC81] [18]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fostamatinib. Thrombocytopenia [3B64] [17]
Eltrombopag DMOGFIX Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Eltrombopag. Thrombocytopenia [3B64] [17]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lenvatinib. Thyroid cancer [2D10] [18]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Epirubicin and Cabozantinib. Thyroid cancer [2D10] [19]
Propylthiouracil DM6D7N8 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Propylthiouracil. Thyrotoxicosis [5A02] [17]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Epirubicin and Papaverine. Tonus and reflex abnormality [MB47] [67]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tizanidine. Tonus and reflex abnormality [MB47] [18]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Epirubicin and Azathioprine. Transplant rejection [NE84] [17]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tacrolimus. Transplant rejection [NE84] [18]
Cinoxacin DM4EWNS Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [26]
Nitrofurantoin DM7PQIK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Nitrofurantoin. Urinary tract infection [GC08] [17]
Nalidixic acid DMRM0JV Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [26]
Enoxacin DMYTE6L Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [26]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Astemizole. Vasomotor/allergic rhinitis [CA08] [18]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [57]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Epirubicin and Procainamide. Ventricular tachyarrhythmia [BC71] [18]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Propafenone. Ventricular tachyarrhythmia [BC71] [18]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Flecainide. Ventricular tachyarrhythmia [BC71] [18]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Epirubicin and Amiodarone. Ventricular tachyarrhythmia [BC71] [18]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Epirubicin and Ganciclovir. Virus infection [1A24-1D9Z] [17]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Epirubicin and Valganciclovir. Virus infection [1A24-1D9Z] [17]
⏷ Show the Full List of 278 DDI Information of This Drug

References

1 New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet Genomics. 2011 Sep;21(9):552-8. doi: 10.1097/FPC.0b013e328348e48f.
6 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res. 2016 Mar;30(2):120-133.
10 Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006 Dec;34(12):2097-101.
11 7,3',4'-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology. 2012 Dec 16;302(2-3):221-32. doi: 10.1016/j.tox.2012.08.003. Epub 2012 Aug 15.
12 Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
13 [Antisense oligonucleotide targeting survivin induces apoptosis of renal clear-cell carcinoma cells and enhances their sensitivity to epirubicin in vitro]. Zhonghua Zhong Liu Za Zhi. 2005 Aug;27(8):468-70.
14 [Knock-down of apollon gene by antisense oligodeoxynucleotide inhibits the proliferation of Lovo cells and enhances chemo-sensitivity]. Yao Xue Xue Bao. 2011 Feb;46(2):138-45.
15 Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999 Dec 1;59(23):5938-46.
16 The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells. Breast Cancer Res Treat. 2003 Aug;80(3):239-44. doi: 10.1023/A:1024995202135.
17 Cerner Multum, Inc. "Australian Product Information.".
18 Canadian Pharmacists Association.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
21 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
22 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
23 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
24 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
25 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
26 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
27 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
28 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
29 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
30 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
31 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
32 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
33 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
34 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
35 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
36 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
37 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
38 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
39 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
40 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
41 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
42 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
44 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
46 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
47 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
48 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
49 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
50 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
51 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
52 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
53 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
55 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
56 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
57 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
58 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
59 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
60 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
61 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
62 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
63 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
64 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
65 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
66 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
67 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]